Evaluation Sub-Committee - Applications scheduled to be considered
- 1593.1 – Bioinductive implant for the repair of rotator cuff tear
- 1728 – Etranacogene dezaparvovec for the treatment of Haemophilia B
- 1732.1 – Imlifidase as a desensitisation treatment to enable kidney transplant in highly sensitised adult transplant candidates
- 1738 – Two testing options to detect early-stage Alzheimer's Disease, to determine eligibility for PBS subsidised lecanemab treatment
- 1743 – Optical coherence tomography (OCT) guided coronary stent insertion for patients eligible for coronary revascularisation
- 1744 – 177Lutetium(nca)-DOTA-octreotate treatment for advanced neuroendocrine tumours and other high somatostatin receptor expressing tumours
- 1750 – Testing of tumour tissue to detect IDH1 mutations in patients with cholangiocarcinoma to determine eligibility for ivosidenib on the Pharmacutical Benefits Scheme
- 1758 - Expansion of MBS item numbers 12320 & 12322 for bone mineral density testing to include patients aged 60-69 years
- 1771 – Axicabtagene ciloleucel therapy for patients with relapsed or refractory follicular lymphoma
Consultation Input:
MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application.It is anticipated that the above-mentioned applications will proceed to MSAC in August 2024. Consultation input must be received by no later than Friday, 14 June 2024 for it to be considered by MSAC. A Consultation Survey Form is available on the relevant application webpage.
Further information on MSAC’s consultation process is also available on the MSAC website.